Acumen Pharmaceuticals

Capital is focused on a single lead program plus platform options. Positive: partnership leverage via JCR for Enhanced Brain Delivery and Lonza manufacturing; SC formulation path with Halozyme; disciplined outsourcing.

Cautions: reliance on equity (ATM, private placement) and high‑cost venture debt; no history yet of returning capital; and the portfolio remains early, so each dollar must fund long‑dated, high‑uncertainty R&D. Overall, reasonable for a clinical‑stage biotech, but below our high bar.